Acquisition Opportunity WCG Clinical acquired Statistics Collaborative in early 2020, indicating a successful integration of biostatistical consulting capabilities into a larger clinical trial solutions provider. This presents cross-sell potential for WCG’s broader client base to engage SCI’s specialized biostatistical services, especially for complex trial designs and FDA submissions.

Specialized Expertise SCI offers deep statistical expertise across trial design, data monitoring committee reporting, randomization schemes, data analysis, and FDA presentation consulting with emphasis on cardiovascular disease, infectious disease, orphan diseases, and vaccines. This positions SCI to win projects requiring rigorous statistical validity and regulatory-focused deliverables.

Financial Scale With annual revenue in the 25 to 50 million range and a mid-size employee base, SCI sits between boutique specialists and larger CROs, offering a compelling value proposition for mid-market sponsors seeking quality statistical services with flexible engagement models.

Industry Positioning As an affiliate of WIRB-Copernicus Group, SCI benefits from an established ethics and compliance framework within a leading clinical trial solutions ecosystem, enabling joint offerings and credibility when pursuing sponsor-led, regulatory-compliant studies.

Expansion Potential The company’s broad therapeutic focus and integration with WCG Clinical creates opportunities to target sponsors expanding portfolios in vaccines and orphan diseases, leveraging SCI’s statistical rigor to support large-scale trials, data analyses, and regulatory submissions.